In the study, empagliflozin demonstrated a 22% relative risk reduction in all-cause hospitalizations vs DPP-4 inhibitors after a mean follow-up of 5.4 months.

Summary A new DPP-4 inhibitor class of oral anti-diabetic medicines, working by the novel mechanism of incretin enhancement, is poised to revolutionise the management of Type 2 diabetes. Data ...

As if last week's Jardiance news wasn't enough to worry makers of DPP-4 diabetes drugs, the FDA has now issued a warning that the class of meds might cause "severe and disabling" joint pain.

Dipeptidyl peptidase 4 (DPP-4) is a homodimeric type II transmembrane receptor identical to the leukocyte surface antigen CD26 and is also present in a soluble, enzymatically active form in plasma ...

This study evaluates the long-term cost-effectiveness of treatment involving combination therapy with dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2 ...

Results showed that DPP-4 inhibitors yielded 0.42 cases of bullous pemphigoid per 1,000 person-years compared with 0.31 cases per 1,000 person-years for sulfonylureas (HR = 1.42; 95% CI, 1.17-1.72).

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Unlike exenatide (Exendin-4), a synthetic version of GLP-1, LAF237 inhibits the action of DPP-4, which rapidly degrades GLP-1. Dr.